Supernus Pharmaceuticals Stock Price on December 13, 2024
| SUPN Stock | USD 35.60 0.01 0.03% |
Below is the normalized historical share price chart for Supernus Pharmaceuticals extending back to May 01, 2012. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Supernus Pharmaceuticals stands at 35.60, as last reported on the 25th of December, with the highest price reaching 35.64 and the lowest price hitting 34.78 during the day.
If you're considering investing in Supernus Stock, it is important to understand the factors that can impact its price. Supernus Pharmaceuticals appears to be very steady, given 3 months investment horizon. Supernus Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.14, which indicates the firm had a 0.14% return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Supernus Pharmaceuticals, which you can use to evaluate the volatility of the company. Please review Supernus Pharmaceuticals' Risk Adjusted Performance of 0.0947, coefficient of variation of 898.17, and Semi Deviation of 1.36 to confirm if our risk estimates are consistent with your expectations.
At this time, Supernus Pharmaceuticals' Total Stockholder Equity is very stable compared to the past year. As of the 25th of December 2024, Capital Stock is likely to grow to about 58.7 K, while Common Stock Shares Outstanding is likely to drop about 42.6 M. . As of the 25th of December 2024, Price Earnings Ratio is likely to grow to 1,259, while Price To Sales Ratio is likely to drop 2.47. Supernus Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 1st of May 2012 | 200 Day MA 31.8409 | 50 Day MA 35.6266 | Beta 0.866 |
Supernus |
Sharpe Ratio = 0.137
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SUPN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.81 actual daily | 16 84% of assets are more volatile |
Expected Return
| 0.25 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Supernus Pharmaceuticals is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Supernus Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 1.9513 | Enterprise Value Ebitda 10.2759 | Price Sales 3.0152 | Shares Float 47.6 M | Wall Street Target Price 39.25 |
Supernus Pharmaceuticals Main Headline on 13th of December 2024
Newron and EA Pharma Announce License Agreement for Evenamid... by businesswire.com
Newron and EA Pharma sign licence for evenamide in Japan Asia. Newron to receive up to 117 million from upfront payments, milestones and royalties.
Supernus Pharmaceuticals Valuation on December 13, 2024
It is possible to determine the worth of Supernus Pharmaceuticals on a given historical date. On December 13, 2024 Supernus was worth 37.28 at the beginning of the trading date compared to the closed value of 36.17. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Supernus Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Supernus Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Supernus Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Supernus Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 36.87 | 36.97 | 36.11 | 36.16 | 507,553 | |
12/13/2024 | 37.28 | 37.28 | 35.68 | 36.17 | 455,557 |
| 36.20 | 37.07 | 35.96 | 36.49 | 369,418 |
| Backtest Supernus Pharmaceuticals | | | Supernus Pharmaceuticals History | | | Supernus Pharmaceuticals Valuation | Previous | Next |
Supernus Pharmaceuticals Trading Date Momentum on December 13, 2024
| On December 16 2024 Supernus Pharmaceuticals was traded for 36.49 at the closing time. The top price for the day was 37.07 and the lowest listed price was 35.96 . The trading volume for the day was 369.4 K. The trading history from December 16, 2024 was a factor to the next trading day price boost. The trading price change against the next closing price was 0.88% . The trading price change against the current closing price is 2.21% . |
Supernus Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Supernus Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Supernus Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Supernus financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Supernus Pharmaceuticals Stock history
Supernus Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Supernus is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Supernus Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Supernus Pharmaceuticals stock prices may prove useful in developing a viable investing in Supernus Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 55.5 M | 42.6 M | |
| Net Income Applicable To Common Shares | 69.8 M | 50.8 M |
Supernus Pharmaceuticals Stock Technical Analysis
Supernus Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Supernus Pharmaceuticals Period Price Range
Low | December 25, 2024
| High |
0.00 | 0.00 |
Supernus Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Supernus Pharmaceuticals December 25, 2024 Market Strength
Market strength indicators help investors to evaluate how Supernus Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Supernus Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Supernus Pharmaceuticals stock market strength indicators, traders can identify Supernus Pharmaceuticals entry and exit signals to maximize returns
Supernus Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Supernus Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Supernus Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Supernus to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0947 | |||
| Jensen Alpha | 0.1603 | |||
| Total Risk Alpha | 0.1156 | |||
| Sortino Ratio | 0.0973 | |||
| Treynor Ratio | 0.1906 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.